- Home
- ALDF vs ETON Comparison
ALDF vs ETON Comparison
Compare ALDF & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDF
- ETON
- Stock Information
- Founded
- ALDF 2024
- ETON 2017
- Country
- ALDF United States
- ETON United States
- Employees
- ALDF N/A
- ETON N/A
- Industry
- ALDF
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- ALDF
- ETON Health Care
- Exchange
- ALDF NYSE
- ETON Nasdaq
- Market Cap
- ALDF 299.9M
- ETON 329.8M
- IPO Year
- ALDF 2024
- ETON 2018
- Fundamental
- Price
- ALDF $10.06
- ETON $15.58
- Analyst Decision
- ALDF
- ETON Strong Buy
- Analyst Count
- ALDF 0
- ETON 3
- Target Price
- ALDF N/A
- ETON $24.00
- AVG Volume (30 Days)
- ALDF 1.5K
- ETON 244.0K
- Earning Date
- ALDF 01-01-0001
- ETON 05-08-2025
- Dividend Yield
- ALDF N/A
- ETON N/A
- EPS Growth
- ALDF N/A
- ETON N/A
- EPS
- ALDF N/A
- ETON N/A
- Revenue
- ALDF N/A
- ETON $34,677,000.00
- Revenue This Year
- ALDF N/A
- ETON $22.19
- Revenue Next Year
- ALDF N/A
- ETON $109.55
- P/E Ratio
- ALDF $79.68
- ETON N/A
- Revenue Growth
- ALDF N/A
- ETON 5.64
- 52 Week Low
- ALDF $9.98
- ETON $3.03
- 52 Week High
- ALDF $11.46
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- ALDF N/A
- ETON 53.40
- Support Level
- ALDF N/A
- ETON $14.28
- Resistance Level
- ALDF N/A
- ETON $15.02
- Average True Range (ATR)
- ALDF 0.00
- ETON 0.93
- MACD
- ALDF 0.00
- ETON -0.00
- Stochastic Oscillator
- ALDF 0.00
- ETON 79.52
About ALDF ALDEL FINL II INC
Aldel Financial II Inc is a Shell Company with various businesses.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.